SRR820209
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR820133 | GTEX | — | 0.960 |
| 2 | SRR1410783 | GTEX | — | 0.948 |
| 3 | SRR1466975 | GTEX | — | 0.933 |
| 4 | SRR1331579 | GTEX | — | 0.919 |
| 5 | 3BCD8BE5-753D-43EF-B830-EA4356620A5C | — | — | 0.911 |
| 6 | SRR821019 | GTEX | — | 0.910 |
| 7 | BS_1JDG6JV5 | pilocytic astrocytoma | — | 0.904 |
| 8 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.900 |
| 9 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.900 |
| 10 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.899 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.720 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.649 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.586 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.525 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.462 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.459 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.431 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.431 | Inavolisib | — uncovered |
| COMPLEMENT | 0.386 | Inavolisib | — uncovered |
| HYPOXIA | 0.382 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.351 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.347 | Idelalisib | — uncovered |
| COAGULATION | 0.345 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.344 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.335 | Idelalisib | — uncovered |
| APOPTOSIS | 0.333 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.325 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.296 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.295 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.289 | Inavolisib | — uncovered |